Clinical Trial Update: Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1/2 trial evaluated an oral rotavirus vaccine (116E) in healthy infants aged 8 to 20 weeks; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea

Drugs mentioned

• ROTAVIRUS vaccine 116E (Rotavirus vaccine 116E)

Snippet

Sponsor: Bharat Biotech International Limited | Conditions: Diarrhea | Phase 1, Phase 2 | Status: COMPLETED